IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses

Immune checkpoint inhibitor (ICI) therapy has revolutionized anti-cancer treatment for many late-stage cancer patients. However, ICI therapy has thus far demonstrated limited efficacy for most patients, and it remains unclear why this is so. Interleukin 10 (IL-10) is a cytokine that has been recogni...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of molecular sciences Vol. 22; no. 21; p. 11848
Main Authors:	Harper, Taylor A., Bacot, Silvia M., Fennell, Christie Jane, Matthews, Rebecca L., Zhu, Christina, Yue, Peng, Benton, Alexander, Friedman, Devira, Akue, Adovi, KuKuruga, Mark A., Lee, Shiowjen, Wang, Tao, Feldman, Gerald M.
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 31.10.2021 MDPI
Subjects:	Apoptosis Cancer Clinical trials Cytokines FDA approval Humans Immunotherapy Interferon-gamma - immunology Interleukin-10 - immunology Interleukin-2 Receptor alpha Subunit - immunology Ki-67 Antigen - immunology Lymphocyte Activation - drug effects Lymphocytes MAP Kinase Signaling System - drug effects MAP Kinase Signaling System - immunology Melanoma Nivolumab - pharmacology T-Lymphocytes - immunology Targeted cancer therapy STAT3 pathway nivolumab AKT serine–threonine kinase pathway MAP kinase pathway cytokines T cells interleukin 10
ISSN:	1422-0067, 1661-6596, 1422-0067
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Immune checkpoint inhibitor (ICI) therapy has revolutionized anti-cancer treatment for many late-stage cancer patients. However, ICI therapy has thus far demonstrated limited efficacy for most patients, and it remains unclear why this is so. Interleukin 10 (IL-10) is a cytokine that has been recognized as a central player in cancer biology with its ability to inhibit anti-tumor T cell responses. Recent studies suggest that IL-10 might also exert some intrinsic anti-tumor T cell responses, and clinical studies using recombinant IL-10 alone or in combination with ICI are underway. This paradoxical effect of IL-10 and its underlying mechanisms impacting ICI-modulated T cell responses remain poorly understood. In this study, using an in vitro mixed lymphocyte reaction assay, we found that treatment with ICIs such as the anti-programmed cell death receptor-1 (PD-1) mAb nivolumab elicits a strong expression of IL-10. While neutralization of IL-10 signaling with an anti-IL-10 specific mAb significantly decreases the production of IFN-γ by T cells in a cohort of donor cells, the opposite effect was observed in other donor cells. Similarly, neutralization of IL-10 signaling significantly decreases the expression of T cell activation markers Ki67 and CD25, as well as the production of Granzyme B in a cohort of donor cells, whereas the opposite effect was observed in others. Furthermore, we found that nivolumab and IL-10 differentially modulate the signal transducer and activator of transcription 3 (STAT3) and AKT serine–threonine kinase pathways. Finally, we found that nivolumab activates the mitogen-activated protein kinase (MAPK) pathway, which in turn is responsible for the observed induction of IL-10 production by nivolumab. These findings provide new insights into the mechanisms underlying anti-PD-1-modulated T cell responses by IL-10, which could lead to the discovery of novel combination treatments that target IL-10 and immune checkpoint molecules.
AbstractList	Immune checkpoint inhibitor (ICI) therapy has revolutionized anti-cancer treatment for many late-stage cancer patients. However, ICI therapy has thus far demonstrated limited efficacy for most patients, and it remains unclear why this is so. Interleukin 10 (IL-10) is a cytokine that has been recognized as a central player in cancer biology with its ability to inhibit anti-tumor T cell responses. Recent studies suggest that IL-10 might also exert some intrinsic anti-tumor T cell responses, and clinical studies using recombinant IL-10 alone or in combination with ICI are underway. This paradoxical effect of IL-10 and its underlying mechanisms impacting ICI-modulated T cell responses remain poorly understood. In this study, using an in vitro mixed lymphocyte reaction assay, we found that treatment with ICIs such as the anti-programmed cell death receptor-1 (PD-1) mAb nivolumab elicits a strong expression of IL-10. While neutralization of IL-10 signaling with an anti-IL-10 specific mAb significantly decreases the production of IFN-γ by T cells in a cohort of donor cells, the opposite effect was observed in other donor cells. Similarly, neutralization of IL-10 signaling significantly decreases the expression of T cell activation markers Ki67 and CD25, as well as the production of Granzyme B in a cohort of donor cells, whereas the opposite effect was observed in others. Furthermore, we found that nivolumab and IL-10 differentially modulate the signal transducer and activator of transcription 3 (STAT3) and AKT serine-threonine kinase pathways. Finally, we found that nivolumab activates the mitogen-activated protein kinase (MAPK) pathway, which in turn is responsible for the observed induction of IL-10 production by nivolumab. These findings provide new insights into the mechanisms underlying anti-PD-1-modulated T cell responses by IL-10, which could lead to the discovery of novel combination treatments that target IL-10 and immune checkpoint molecules. Immune checkpoint inhibitor (ICI) therapy has revolutionized anti-cancer treatment for many late-stage cancer patients. However, ICI therapy has thus far demonstrated limited efficacy for most patients, and it remains unclear why this is so. Interleukin 10 (IL-10) is a cytokine that has been recognized as a central player in cancer biology with its ability to inhibit anti-tumor T cell responses. Recent studies suggest that IL-10 might also exert some intrinsic anti-tumor T cell responses, and clinical studies using recombinant IL-10 alone or in combination with ICI are underway. This paradoxical effect of IL-10 and its underlying mechanisms impacting ICI-modulated T cell responses remain poorly understood. In this study, using an in vitro mixed lymphocyte reaction assay, we found that treatment with ICIs such as the anti-programmed cell death receptor-1 (PD-1) mAb nivolumab elicits a strong expression of IL-10. While neutralization of IL-10 signaling with an anti-IL-10 specific mAb significantly decreases the production of IFN-γ by T cells in a cohort of donor cells, the opposite effect was observed in other donor cells. Similarly, neutralization of IL-10 signaling significantly decreases the expression of T cell activation markers Ki67 and CD25, as well as the production of Granzyme B in a cohort of donor cells, whereas the opposite effect was observed in others. Furthermore, we found that nivolumab and IL-10 differentially modulate the signal transducer and activator of transcription 3 (STAT3) and AKT serine-threonine kinase pathways. Finally, we found that nivolumab activates the mitogen-activated protein kinase (MAPK) pathway, which in turn is responsible for the observed induction of IL-10 production by nivolumab. These findings provide new insights into the mechanisms underlying anti-PD-1-modulated T cell responses by IL-10, which could lead to the discovery of novel combination treatments that target IL-10 and immune checkpoint molecules.Immune checkpoint inhibitor (ICI) therapy has revolutionized anti-cancer treatment for many late-stage cancer patients. However, ICI therapy has thus far demonstrated limited efficacy for most patients, and it remains unclear why this is so. Interleukin 10 (IL-10) is a cytokine that has been recognized as a central player in cancer biology with its ability to inhibit anti-tumor T cell responses. Recent studies suggest that IL-10 might also exert some intrinsic anti-tumor T cell responses, and clinical studies using recombinant IL-10 alone or in combination with ICI are underway. This paradoxical effect of IL-10 and its underlying mechanisms impacting ICI-modulated T cell responses remain poorly understood. In this study, using an in vitro mixed lymphocyte reaction assay, we found that treatment with ICIs such as the anti-programmed cell death receptor-1 (PD-1) mAb nivolumab elicits a strong expression of IL-10. While neutralization of IL-10 signaling with an anti-IL-10 specific mAb significantly decreases the production of IFN-γ by T cells in a cohort of donor cells, the opposite effect was observed in other donor cells. Similarly, neutralization of IL-10 signaling significantly decreases the expression of T cell activation markers Ki67 and CD25, as well as the production of Granzyme B in a cohort of donor cells, whereas the opposite effect was observed in others. Furthermore, we found that nivolumab and IL-10 differentially modulate the signal transducer and activator of transcription 3 (STAT3) and AKT serine-threonine kinase pathways. Finally, we found that nivolumab activates the mitogen-activated protein kinase (MAPK) pathway, which in turn is responsible for the observed induction of IL-10 production by nivolumab. These findings provide new insights into the mechanisms underlying anti-PD-1-modulated T cell responses by IL-10, which could lead to the discovery of novel combination treatments that target IL-10 and immune checkpoint molecules.
Author	Fennell, Christie Jane Akue, Adovi KuKuruga, Mark A. Zhu, Christina Bacot, Silvia M. Wang, Tao Matthews, Rebecca L. Yue, Peng Benton, Alexander Feldman, Gerald M. Harper, Taylor A. Friedman, Devira Lee, Shiowjen
AuthorAffiliation	2 Office of Vaccines Research & Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA; Adovi.Akue@fda.hhs.gov (A.A.); Mark.Kukuruga@fda.hhs.gov (M.A.K.); Shiowjen.Lee@fda.hhs.gov (S.L.) 1 Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA; tah9h@virginia.edu (T.A.H.); Silvia.Bacot@fda.hhs.gov (S.M.B.); ChristieJane.Fennell@fda.hhs.gov (C.J.F.); rebecca.matthews@nih.gov (R.L.M.); Christina.Zhu@fda.hhs.gov (C.Z.); shandongyuepeng@hotmail.com (P.Y.); alexander.benton@okstate.edu (A.B.); dsf2141@barnard.edu (D.F.)
AuthorAffiliation_xml	– name: 2 Office of Vaccines Research & Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA; Adovi.Akue@fda.hhs.gov (A.A.); Mark.Kukuruga@fda.hhs.gov (M.A.K.); Shiowjen.Lee@fda.hhs.gov (S.L.) – name: 1 Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA; tah9h@virginia.edu (T.A.H.); Silvia.Bacot@fda.hhs.gov (S.M.B.); ChristieJane.Fennell@fda.hhs.gov (C.J.F.); rebecca.matthews@nih.gov (R.L.M.); Christina.Zhu@fda.hhs.gov (C.Z.); shandongyuepeng@hotmail.com (P.Y.); alexander.benton@okstate.edu (A.B.); dsf2141@barnard.edu (D.F.)
Author_xml	– sequence: 1 givenname: Taylor A. orcidid: 0000-0002-6088-1028 surname: Harper fullname: Harper, Taylor A. – sequence: 2 givenname: Silvia M. surname: Bacot fullname: Bacot, Silvia M. – sequence: 3 givenname: Christie Jane orcidid: 0000-0002-2229-6848 surname: Fennell fullname: Fennell, Christie Jane – sequence: 4 givenname: Rebecca L. surname: Matthews fullname: Matthews, Rebecca L. – sequence: 5 givenname: Christina surname: Zhu fullname: Zhu, Christina – sequence: 6 givenname: Peng surname: Yue fullname: Yue, Peng – sequence: 7 givenname: Alexander orcidid: 0000-0002-4421-0179 surname: Benton fullname: Benton, Alexander – sequence: 8 givenname: Devira surname: Friedman fullname: Friedman, Devira – sequence: 9 givenname: Adovi surname: Akue fullname: Akue, Adovi – sequence: 10 givenname: Mark A. surname: KuKuruga fullname: KuKuruga, Mark A. – sequence: 11 givenname: Shiowjen surname: Lee fullname: Lee, Shiowjen – sequence: 12 givenname: Tao orcidid: 0000-0002-1153-3430 surname: Wang fullname: Wang, Tao – sequence: 13 givenname: Gerald M. surname: Feldman fullname: Feldman, Gerald M.
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/34769278$$D View this record in MEDLINE/PubMed
BookMark	eNptkktvEzEUhUeoiD5gyRZZYsNmwI95eDZIUegjIi0VlLV1x3OTOHLsdOwJyt_hl9ZNW5RWrGzZ3z0-1-ceZwfOO8yy94x-FqKhX8xyFTjnjDFZyFfZESs4zymt6oO9_WF2HMKSUi542bzJDkVRVw2v5VH2dzLNGSW_zNyBNW5OTq3RJmJH2i25MhtvhxW0-cR1g06HIx3NBqLxjvgZiQskl6Nr8t04CEiuIS7-wJZ88xjIlY_kbLB2S8bexd60Q0QS_Z7mpe8GC_dPXWDE3s_RoR8CuSFjtJb8xLD2LmB4m72egQ347nE9yX6fnd6ML_Lpj_PJeDTNdcHKmIuCVi2ihKormrKmraSygaZtJEiKHHVVQoMADAE101XTtqKSrdCsBt1QECfZ1wfd9dCusNOYbINV696soN8qD0Y9v3FmoeZ-o2QpCyZYEvj0KND72wFDVCsTdOoFdo2p9Pd1ISWvyoR-fIEu_dCnCHZURYXkRZ2oD_uO_ll5ii8B4gHQvQ-hx5lK2e3iSQaNVYyq-yFRz4YkVeUvqp6E_8_fASMewL4
CitedBy_id	crossref_primary_10_1186_s12863_022_01073_7 crossref_primary_10_1016_j_bbrc_2024_151137 crossref_primary_10_1007_s11259_023_10158_2 crossref_primary_10_1016_j_apsb_2024_07_024 crossref_primary_10_1177_17588359221126154 crossref_primary_10_1007_s00262_024_03635_3
Cites_doi	10.1146/annurev.immunol.19.1.683 10.3389/fimmu.2018.01923 10.1158/1078-0432.CCR-17-2267 10.1038/nrc3239 10.1007/s12026-011-8262-6 10.1146/annurev-immunol-031210-101312 10.3389/fimmu.2016.00550 10.1146/annurev.immunol.22.012703.104622 10.1038/bjc.2017.434 10.1038/nri2711 10.1016/j.it.2016.01.004 10.1097/CCO.0000000000000006 10.1111/cas.13226 10.1038/s41598-020-72711-2 10.1056/NEJMra1514296 10.1158/2159-8290.CD-18-0367 10.1073/pnas.94.10.5326 10.1038/nri.2017.108 10.1016/j.cell.2017.01.017 10.1126/science.aaf1292 10.1097/00007890-199710150-00012 10.1016/0008-8749(84)90251-X 10.1016/j.immuni.2011.03.018 10.1016/S1470-2045(19)30514-5 10.1016/j.it.2006.01.007 10.1016/j.ccr.2011.11.020 10.1002/jcp.27172 10.3390/ijms21239023 10.1016/j.ccr.2011.11.003 10.1158/2326-6066.CIR-13-0078 10.1016/S1470-2045(17)30607-1 10.1158/0008-5472.CAN-14-2538 10.1016/j.ebiom.2017.02.004 10.1056/NEJMoa1003466 10.1126/science.aar4060 10.1016/j.immuni.2016.06.001 10.1016/j.immuni.2019.03.020 10.1038/ncomms14236 10.1038/s41467-017-00728-9 10.1200/JCO.2016.68.1106 10.1158/2326-6066.CIR-13-0214 10.1080/2162402X.2018.1512456 10.4049/jimmunol.154.10.5492 10.1111/j.1600-065X.2008.00706.x 10.1158/0008-5472.CAN-17-0740 10.1053/gast.2000.20196 10.1182/blood-2006-02-002774 10.1038/s41375-021-01217-1 10.1371/journal.pone.0167251 10.1158/2326-6066.CIR-14-0040 10.1146/annurev-cancerbio-030419-033604 10.1158/0008-5472.CAN-14-3016
ContentType	Journal Article
Copyright	2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2021 by the authors. 2021
Copyright_xml	– notice: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2021 by the authors. 2021
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. M0S M1P M2O MBDVC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM
DOI	10.3390/ijms222111848
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database Research Library Research Library (Corporate) ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic Publicly Available Content Database CrossRef
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Biology
EISSN	1422-0067
ExternalDocumentID	PMC8584131 34769278 10_3390_ijms222111848
Genre	Journal Article
GroupedDBID	--- 29J 2WC 53G 5GY 5VS 7X7 88E 8FE 8FG 8FH 8FI 8FJ 8G5 A8Z AADQD AAFWJ AAHBH AAYXX ABDBF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AFFHD AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU CITATION CS3 D1I DIK DU5 DWQXO E3Z EBD EBS EJD ESX F5P FRP FYUFA GNUQQ GUQSH GX1 HH5 HMCUK HYE IAO IHR ITC KQ8 LK8 M1P M2O M48 MODMG O5R O5S OK1 OVT P2P PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO RNS RPM TR2 TUS UKHRP ~8M ALIPV CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK ESTFP K9. MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c415t-3406bee8a6d49570b8089a9b98a80e2ec65a9eaa1eaec1c69bb368b3c17ac90a3
IEDL.DBID	7X7
ISICitedReferencesCount	5
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000719512700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1422-0067 1661-6596
IngestDate	Tue Nov 04 02:00:17 EST 2025 Fri Sep 05 07:48:48 EDT 2025 Tue Oct 07 07:28:11 EDT 2025 Thu Apr 03 07:05:10 EDT 2025 Tue Nov 18 22:41:01 EST 2025 Sat Nov 29 07:13:18 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	21
Keywords	STAT3 pathway nivolumab AKT serine–threonine kinase pathway MAP kinase pathway cytokines T cells interleukin 10
Language	English
License	Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c415t-3406bee8a6d49570b8089a9b98a80e2ec65a9eaa1eaec1c69bb368b3c17ac90a3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Present Affiliation: Department of Biochemistry, Oklahoma State University, Stillwater, OK 74075, USA. Present Affiliation: Flow Cytometry Core Facility, School of Medicine, University of Virginia, Charlottesville, VA 22903, USA. Present Affiliation: Department of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Present Affiliation: Cancer ImmunoPrevention Laboratory, Vaccine, Immunity, and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA. Present Affiliation: Barnard College, New York, NY 10027, USA.
ORCID	0000-0002-6088-1028 0000-0002-1153-3430 0000-0002-4421-0179 0000-0002-2229-6848
OpenAccessLink	https://www.proquest.com/docview/2596038247?pq-origsite=%requestingapplication%
PMID	34769278
PQID	2596038247
PQPubID	2032341
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_8584131 proquest_miscellaneous_2597488265 proquest_journals_2596038247 pubmed_primary_34769278 crossref_citationtrail_10_3390_ijms222111848 crossref_primary_10_3390_ijms222111848
PublicationCentury	2000
PublicationDate	20211031
PublicationDateYYYYMMDD	2021-10-31
PublicationDate_xml	– month: 10 year: 2021 text: 20211031 day: 31
PublicationDecade	2020
PublicationPlace	Switzerland
PublicationPlace_xml	– name: Switzerland – name: Basel
PublicationTitle	International journal of molecular sciences
PublicationTitleAlternate	Int J Mol Sci
PublicationYear	2021
Publisher	MDPI AG MDPI
Publisher_xml	– name: MDPI AG – name: MDPI
References	Mosser (ref_12) 2008; 226 Brahmer (ref_1) 2013; 1 Jenkins (ref_7) 2018; 118 Syn (ref_42) 2017; 18 Yamazaki (ref_27) 2017; 108 Dushyanthen (ref_40) 2017; 8 Boussiotis (ref_37) 2016; 375 Schnorr (ref_34) 1997; 94 Wang (ref_51) 2015; 128 Salmond (ref_53) 2006; 27 Walter (ref_46) 2014; 380 Kumar (ref_50) 2016; 37 Sharpe (ref_35) 2018; 18 Ganesan (ref_48) 2020; 4 Wissing (ref_22) 1997; 64 Wei (ref_43) 2018; 8 Sharma (ref_6) 2017; 168 Dermani (ref_39) 2019; 234 Makkouk (ref_3) 2015; 75 ref_20 Scandiuzzi (ref_32) 2017; 17 Moore (ref_13) 2001; 19 Hodi (ref_2) 2010; 363 Yue (ref_55) 2017; 8 Mumm (ref_16) 2011; 20 Naing (ref_29) 2019; 20 Ribas (ref_5) 2018; 359 Pardoll (ref_4) 2012; 12 Pitt (ref_8) 2016; 44 Smeets (ref_24) 1999; 26 ref_30 Rivas (ref_26) 2021; 35 Teng (ref_11) 2011; 20 Beyer (ref_18) 2006; 108 ref_38 Naing (ref_19) 2016; 34 Schreiber (ref_23) 2000; 119 Gide (ref_41) 2018; 24 Hui (ref_36) 2017; 355 Pestka (ref_47) 2004; 22 Yue (ref_33) 2019; 8 Ouyang (ref_44) 2011; 29 Sun (ref_15) 2015; 75 Dennis (ref_17) 2013; 25 Chernoff (ref_21) 1995; 154 Lamichhane (ref_25) 2017; 77 ref_45 Chaudhry (ref_49) 2011; 34 Sato (ref_52) 2011; 51 Ouyang (ref_9) 2019; 50 Giunta (ref_28) 2020; 10 Wang (ref_31) 2014; 2 Oft (ref_10) 2014; 2 Saraiva (ref_14) 2010; 10 Wahl (ref_54) 1984; 85
References_xml	– volume: 19 start-page: 683 year: 2001 ident: ref_13 article-title: Interleukin-10 and the Interleukin-10 Receptor publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev.immunol.19.1.683 – ident: ref_20 doi: 10.3389/fimmu.2018.01923 – volume: 24 start-page: 1260 year: 2018 ident: ref_41 article-title: Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-17-2267 – volume: 12 start-page: 252 year: 2012 ident: ref_4 article-title: The blockade of immune checkpoints in cancer immunotherapy publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3239 – volume: 51 start-page: 170 year: 2011 ident: ref_52 article-title: Interleukin 10 in the tumor microenvironment: A target for anticancer immunotherapy publication-title: Immunol. Res. doi: 10.1007/s12026-011-8262-6 – volume: 380 start-page: 191 year: 2014 ident: ref_46 article-title: The molecular basis of IL-10 function: From receptor structure to the onset of signaling publication-title: Curr. Top. Microbiol. Immunol. – volume: 29 start-page: 71 year: 2011 ident: ref_44 article-title: Regulation and functions of the IL-10 family of cytokines in inflammation and disease publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev-immunol-031210-101312 – ident: ref_38 doi: 10.3389/fimmu.2016.00550 – volume: 22 start-page: 929 year: 2004 ident: ref_47 article-title: Interleukin-10 and Related Cytokines and Receptors publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev.immunol.22.012703.104622 – volume: 118 start-page: 9 year: 2018 ident: ref_7 article-title: Mechanisms of resistance to immune checkpoint inhibitors publication-title: Br. J. Cancer doi: 10.1038/bjc.2017.434 – volume: 10 start-page: 170 year: 2010 ident: ref_14 article-title: The regulation of IL-10 production by immune cells publication-title: Nat. Rev. Immunol. doi: 10.1038/nri2711 – volume: 37 start-page: 208 year: 2016 ident: ref_50 article-title: The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment publication-title: Trends Immunol. doi: 10.1016/j.it.2016.01.004 – volume: 25 start-page: 637 year: 2013 ident: ref_17 article-title: Current status of interleukin-10 and regulatory T-cells in cancer publication-title: Curr. Opin. Oncol. doi: 10.1097/CCO.0000000000000006 – volume: 128 start-page: 95 year: 2015 ident: ref_51 article-title: Chapter Three—Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment publication-title: Advances in Cancer Research – volume: 108 start-page: 1022 year: 2017 ident: ref_27 article-title: Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma publication-title: Cancer Sci. doi: 10.1111/cas.13226 – volume: 10 start-page: 17626 year: 2020 ident: ref_28 article-title: Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients publication-title: Sci. Rep. doi: 10.1038/s41598-020-72711-2 – volume: 375 start-page: 1767 year: 2016 ident: ref_37 article-title: Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra1514296 – volume: 8 start-page: 1069 year: 2018 ident: ref_43 article-title: Fundamental Mechanisms of Immune Checkpoint Blockade Therapy publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-18-0367 – volume: 94 start-page: 5326 year: 1997 ident: ref_34 article-title: Induction of maturation of human blood dendritic cell precursors by measles virus is associated with immunosuppression publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.94.10.5326 – volume: 18 start-page: 153 year: 2018 ident: ref_35 article-title: The diverse functions of the PD1 inhibitory pathway publication-title: Nat. Rev. Immunol. doi: 10.1038/nri.2017.108 – volume: 168 start-page: 707 year: 2017 ident: ref_6 article-title: Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy publication-title: Cell doi: 10.1016/j.cell.2017.01.017 – volume: 355 start-page: 1428 year: 2017 ident: ref_36 article-title: T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition publication-title: Science doi: 10.1126/science.aaf1292 – volume: 64 start-page: 999 year: 1997 ident: ref_22 article-title: A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy publication-title: Transplantation doi: 10.1097/00007890-199710150-00012 – volume: 85 start-page: 373 year: 1984 ident: ref_54 article-title: Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation (CCE). I. Characterization of B-lymphocyte-, T-lymphocyte-, and monocyte-enriched fractions by flow cytometric analysis publication-title: Cell Immunol. doi: 10.1016/0008-8749(84)90251-X – volume: 34 start-page: 566 year: 2011 ident: ref_49 article-title: Interleukin-10 Signaling in Regulatory T Cells Is Required for Suppression of Th17 Cell-Mediated Inflammation publication-title: Immunity doi: 10.1016/j.immuni.2011.03.018 – volume: 20 start-page: 1544 year: 2019 ident: ref_29 article-title: Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): A multicentre, multicohort, open-label, phase 1b trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(19)30514-5 – volume: 27 start-page: 154 year: 2006 ident: ref_53 article-title: SHP2 forecast for the immune system: Fog gradually clearing publication-title: Trends Immunol. doi: 10.1016/j.it.2006.01.007 – volume: 20 start-page: 691 year: 2011 ident: ref_11 article-title: Stable IL-10: A new therapeutic that promotes tumor immunity publication-title: Cancer Cell doi: 10.1016/j.ccr.2011.11.020 – volume: 234 start-page: 1313 year: 2019 ident: ref_39 article-title: PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy publication-title: J. Cell. Physiol. doi: 10.1002/jcp.27172 – ident: ref_45 doi: 10.3390/ijms21239023 – volume: 20 start-page: 781 year: 2011 ident: ref_16 article-title: IL-10 elicits IFNgamma-dependent tumor immune surveillance publication-title: Cancer Cell doi: 10.1016/j.ccr.2011.11.003 – volume: 1 start-page: 85 year: 2013 ident: ref_1 article-title: Immune checkpoint inhibitors: Making immunotherapy a reality for the treatment of lung cancer publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-13-0078 – volume: 18 start-page: e731 year: 2017 ident: ref_42 article-title: De-novo and acquired resistance to immune checkpoint targeting publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(17)30607-1 – volume: 75 start-page: 5 year: 2015 ident: ref_3 article-title: Cancer immunotherapy and breaking immune tolerance: New approaches to an old challenge publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-14-2538 – volume: 17 start-page: 30 year: 2017 ident: ref_32 article-title: Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy publication-title: EBioMedicine doi: 10.1016/j.ebiom.2017.02.004 – volume: 363 start-page: 711 year: 2010 ident: ref_2 article-title: Improved survival with ipilimumab in patients with metastatic melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1003466 – volume: 359 start-page: 1350 year: 2018 ident: ref_5 article-title: Cancer immunotherapy using checkpoint blockade publication-title: Science doi: 10.1126/science.aar4060 – volume: 44 start-page: 1255 year: 2016 ident: ref_8 article-title: Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors publication-title: Immunity doi: 10.1016/j.immuni.2016.06.001 – volume: 50 start-page: 871 year: 2019 ident: ref_9 article-title: IL-10 Family Cytokines IL-10 and IL-22: From Basic Science to Clinical Translation publication-title: Immunity doi: 10.1016/j.immuni.2019.03.020 – volume: 8 start-page: 14236 year: 2017 ident: ref_55 article-title: Sec3 promotes the initial binary t-SNARE complex assembly and membrane fusion publication-title: Nat. Commun. doi: 10.1038/ncomms14236 – volume: 8 start-page: 606 year: 2017 ident: ref_40 article-title: Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer publication-title: Nat. Commun. doi: 10.1038/s41467-017-00728-9 – volume: 34 start-page: 3562 year: 2016 ident: ref_19 article-title: Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.68.1106 – volume: 2 start-page: 194 year: 2014 ident: ref_10 article-title: IL-10: Master switch from tumor-promoting inflammation to antitumor immunity publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-13-0214 – volume: 8 start-page: e1512456 year: 2019 ident: ref_33 article-title: BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways publication-title: OncoImmunology doi: 10.1080/2162402X.2018.1512456 – volume: 154 start-page: 5492 year: 1995 ident: ref_21 article-title: A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses publication-title: J. Immunol. doi: 10.4049/jimmunol.154.10.5492 – volume: 226 start-page: 205 year: 2008 ident: ref_12 article-title: Interleukin-10: New perspectives on an old cytokine publication-title: Immunol. Rev. doi: 10.1111/j.1600-065X.2008.00706.x – volume: 77 start-page: 6667 year: 2017 ident: ref_25 article-title: IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-0740 – volume: 119 start-page: 1461 year: 2000 ident: ref_23 article-title: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Crohn’s Disease IL-10 Cooperative Study Group publication-title: Gastroenterology doi: 10.1053/gast.2000.20196 – volume: 108 start-page: 804 year: 2006 ident: ref_18 article-title: Regulatory T cells in cancer publication-title: Blood doi: 10.1182/blood-2006-02-002774 – volume: 35 start-page: 3188 year: 2021 ident: ref_26 article-title: Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia publication-title: Leukemia doi: 10.1038/s41375-021-01217-1 – ident: ref_30 doi: 10.1371/journal.pone.0167251 – volume: 26 start-page: 2089 year: 1999 ident: ref_24 article-title: Analysis of serial synovial biopsies in patients with rheumatoid arthritis: Description of a control group without clinical improvement after treatment with interleukin 10 or placebo publication-title: J. Rheumatol. – volume: 2 start-page: 846 year: 2014 ident: ref_31 article-title: In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-14-0040 – volume: 4 start-page: 331 year: 2020 ident: ref_48 article-title: Biomarkers for Response to Immune Checkpoint Blockade publication-title: Annu. Rev. Cancer Biol. doi: 10.1146/annurev-cancerbio-030419-033604 – volume: 75 start-page: 1635 year: 2015 ident: ref_15 article-title: IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-14-3016
SSID	ssj0023259
Score	2.3585582
Snippet	Immune checkpoint inhibitor (ICI) therapy has revolutionized anti-cancer treatment for many late-stage cancer patients. However, ICI therapy has thus far...
SourceID	pubmedcentral proquest pubmed crossref
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source
StartPage	11848
SubjectTerms	Apoptosis Cancer Clinical trials Cytokines FDA approval Humans Immunotherapy Interferon-gamma - immunology Interleukin-10 - immunology Interleukin-2 Receptor alpha Subunit - immunology Ki-67 Antigen - immunology Lymphocyte Activation - drug effects Lymphocytes MAP Kinase Signaling System - drug effects MAP Kinase Signaling System - immunology Melanoma Nivolumab - pharmacology T-Lymphocytes - immunology Targeted cancer therapy
Title	IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses
URI	https://www.ncbi.nlm.nih.gov/pubmed/34769278 https://www.proquest.com/docview/2596038247 https://www.proquest.com/docview/2597488265 https://pubmed.ncbi.nlm.nih.gov/PMC8584131
Volume	22
WOSCitedRecordID	wos000719512700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1422-0067 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0023259 issn: 1422-0067 databaseCode: 7X7 dateStart: 20000301 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1422-0067 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0023259 issn: 1422-0067 databaseCode: BENPR dateStart: 20000301 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1422-0067 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0023259 issn: 1422-0067 databaseCode: PIMPY dateStart: 20000301 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1422-0067 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0023259 issn: 1422-0067 databaseCode: M2O dateStart: 20000301 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLZgA4kX7mOFMRkJ8YS1JE5t5wmV0WkTa4jGkMpTZDvOCOrisWSg_h1-KcdO2rUgeOElUmLHiXJu30lOzofQy4iVMWdlQZgQlMSF0UTxghEhIZgMS6M49T8KH_M0FdNpkvUv3Jq-rHLhE72jLqx278j3AKazgIoo5m8uvhHHGuW-rvYUGjfRpqPNdnrOp9cJF408WVoIMYgwOL_rsUkhzd-rvp43EBrB0oWj_lmNSX8Azd_rJVcC0MG9_731--huDz3xqNOVB-iGqR-i2x0Z5fwR-nl0DN4Sf6zOHDavz_B4VmkHSLGa47Tybkwq4rg-NBwc6QUxGrYlBhiJJ6MMv69qCIs4A1z5Q87xO2sanNoWu0x3jl0rLE-wZXBrV9ac2MKxiMGqh646x4JSG3vV4FO8b2YzfNLV8ZrmMfp0MD7dPyQ9gwPRAAxaQgEuKGOEZAUkYjxQIhCJTFQipAhMZDQbysRIGRppdKhZohRlQlEdcqmTQNIttFHb2mwjHAgel1qwQEGCF4ZKxEZSwbnmVBRMJwP0eiHDXPftzR3LxiyHNMeJPF8T-QC9Wk6_6Pp6_G3izkKoeW_eTX4t0QF6sRwGw3RfW6R_RG4OB-8YseEAPen0Z3klCvaRRBwW52uatZzgmn6vj9TVF9_8WwBiDGn49N-39QzdiVzxjQ-yO2ijvbwyz9Et_b2tmstdbyV-K3bR5ttxmp3A3iT6AHvZ0ST7_AvJkiMc
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lj9MwEB4tXRBceD8KCxgJOBFtEqe2c0Co2oda9aEIirScgu24S1BJlk2WVf4OP4DfyDhpSguC2x64xpZjOZ_nm4nH8wE899k84GyeOEwI6gSJ0Y7iCXOERDLpzY3itL4oPObTqTg6CqMt-NHehbFpla1NrA11kmv7j3wX3XTmUuEH_M3JV8eqRtnT1VZCo4HFyFTnGLIVr4f7-H1f-P7hwWxv4CxVBRyNZFU6FClMGSMkSzA44K4SrghlqEIhhWt8o1lPhkZKz0ijPc1CpSgTimqPSx26kuK4l2A7sGDvwHY0nEQfViEe9Wt5Ng9Zz2E446aqJ6Whu5t-_lIgGaNtEVZsaJ0F_3Btf8_QXKO8wxv_22LdhOtL55r0m91wC7ZMdhuuNHKb1R34PhwjH5B36bGNPrJjcrBItXW5iarINK0NtVSOVTPR-LCvW-k3ks8JOspk0o_IKM2Q-EmEnvO5rMh-bgoyzUtiY_mK2GJftYSYIWW-NuYkT6xOGo46sPlHOW5bk58VZEb2zGJB3jaZyqa4C-8vZIHuQSfLM_MAiCt4MNeCuQpDWM9TIjCSCs41pyJhOuzCqxYzsV4WcLc6IosYAzkLsXgDYl14uep-0lQu-VvHnRZE8dKAFfEvBHXh2aoZTY89T5L1Etk-HO2_z3pduN_gdfUmihYg9DkOzjeQvOpgy5pvtmTpp7q8uUCf2KPew39P6ylcHcwm43g8nI4ewTXfphrVLsUOdMrTM_MYLutvZVqcPlnuUQIfLxrpPwGloH5n
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1db9MwFL0aHSBe-P4oDDAS8ETUJE5t5wGhal21ql0VwZDGU7AdZwSVZCwdU_8OP4Nfx3U-SguCtz3wmlhO5Bzfc25ycw_Ac5-lAWdp4jAhqBMkRjuKJ8wREsmknxrFafWj8JTPZuLoKIy24Ef7L4wtq2xjYhWok0Lbd-Q9lOnMpcIPeC9tyiKi4ejNyVfHOkjZL62tnUYNkYlZnmP6Vr4eD_FZv_D90d7h7r7TOAw4Golr4VCkM2WMkCzBRIG7SrgilKEKhRSu8Y1mfRkaKT0jjfY0C5WiTCiqPS516EqK816CbZTkgd-B7Wh8EH1YpXvUr6zaPGRAh-Hd1x0-KQ3dXvb5S4nEjHFGWOOhdUb8Q-b-Xq25Rn-jG__zwt2E643oJoN6l9yCLZPfhiu1DefyDnwfT5EnyLvs2GYl-THZm2faSnGilmSWVQFcKse6nGg8ONCtJRwpUoICmhwMIjLJchQEJEJFfS6XZFiYksyKBbE5_pLYJmCVtZghi2JtzoMisf5pOOu-rUsqcDub4qwkh2TXzOfkbV3BbMq78P5CFugedPIiNw-AuIIHqRbMVZjaep4SgZFUcK45FQnTYRdetfiJddPY3fqLzGNM8Czc4g24deHlavhJ3dHkbwN3WkDFTWAr419o6sKz1WkMSfY7k6yWyI7hyAs-63fhfo3d1ZUoRobQ5zg530D1aoBtd755Js8-VW3PBWplj3oP_31bT-EqwjuejmeTR3DNtxVIldLYgc7i9Mw8hsv62yIrT58025XAx4sG-k-pU4cn
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=IL-10+Signaling+Elicited+by+Nivolumab-Induced+Activation+of+the+MAP+Kinase+Pathway+Does+Not+Fully+Contribute+to+Nivolumab-Modulated+Heterogeneous+T+Cell+Responses&rft.jtitle=International+journal+of+molecular+sciences&rft.au=Harper%2C+Taylor+A&rft.au=Bacot%2C+Silvia+M&rft.au=Fennell%2C+Christie+Jane&rft.au=Matthews%2C+Rebecca+L&rft.date=2021-10-31&rft.issn=1422-0067&rft.eissn=1422-0067&rft.volume=22&rft.issue=21&rft_id=info:doi/10.3390%2Fijms222111848&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1422-0067&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1422-0067&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1422-0067&client=summon